Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06706232 · ClinicalTrials.gov registry record · Phase 2
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
A Phase 2 study of Bipolar II Disorder and Depression, Bipolar, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06706232 is a Phase 2 study of Bipolar II Disorder and Depression, Bipolar that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 10 participants, below the 87-participant average among 13 other Bipolar II Disorder trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06706232, a Phase 2 study of Bipolar II Disorder and Depression, Bipolar, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
Conditions Studied
Interventions
- DRUG Psilocybin
- BEHAVIORAL Therapeutic Support
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06706232
The ClinicalTrials.gov registry entry for NCT06706232 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 13 other Bipolar II Disorder trials with a reported enrollment target (89% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bipolar II Disorder appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin is the first listed.
NCT06706232 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06706232 about?
NCT06706232 is a clinical study titled "Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality". The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
What is the current status of trial NCT06706232?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-07-07. Estimated completion is 2027-01.
What conditions does trial NCT06706232 study?
This clinical trial studies the following conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality.
What interventions are being tested in trial NCT06706232?
The interventions under investigation include: Psilocybin (DRUG), Therapeutic Support (BEHAVIORAL).
Who is sponsoring clinical trial NCT06706232?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06706232 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar II Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
RECRUITING · Phase 2
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Bipolar II Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.